-
Schlingensiepen, K.-H. et. al., Targeted Downregulation of TGF-beta 2 with AP 12009 in Tumor Therapy, From: Cancer Drug Discovery and Development: Transforming Growth Factor-beta in Cancer Therapy, Vol II: Cancer Treatment and Therapy, Chapter 38, Pages 635-651, Humana Press Inc. (2008)
-
Schlingensiepen, K.-H. et. al., Antisense Therapeutics for Tumor Treatment - The TGF-beta2 Inhibitor AP 12009 in Clinical Development against Malignant Tumors, From: Pancreatic Cancer, Part III: New Treatment Strategies and Outlook, Chapter 16, Pages 137-150, Springer (2008)
- Schlingensiepen K.-H. et al., Antisense-Nukleinsäuren in der Therapie maligner Tumoren. In: Zeller WJ, zur Hausen H, editors. Onkologie: Grundlagen - Diagnostik - Therapie - Entwicklungen. Landsberg/Lech: Ecomed; 2010. p. IV-20.
- Bogdahn U. et al., Targeted Therapy for High-Grade Glioma with the TGF-β2 Inhibitor Trabedersen: Results of a Randomized and Controlled Phase IIb Study. Neuro-Oncology, 2010, in press.
-
Schlingensiepen, K.-H. et. al., Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009, Cytokine Growth Factor Reviews 17 (2006): 129-139
-
Schlingensiepen, R. et. al., Intracerebral and Intrathecal Infusion of the TGF-beta2-Specific Antisense Phosphorothioate Oligonucleotide AP 12009 in Rabbits and Primates: Toxicology and Safety,
Oligonucleotides 15 (2005): 94-104
-
Schlingensiepen, R. et. al., Immuntherapie gegen Maligne Tumore mit Antisense
AP 12009:
Technologie, Target, Therapie, Journal Onkologie 07 (2005): 24-30
-
Jachimczak, P. et al., Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides, Int J Cancer 65 (1996): 332-337
-
Jachimczak, P. et al., The effect of transforming growth factor-beta 2-specific phosphorothioate-antisense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma,
J Neurosurg 78 (1993): 944-951
|